Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,239

Document Document Title
WO/2021/039800A1
Provided is an enantiomer preparation method in which one enantiomer of a sulfoxide compound is selectively prepared, the sulfoxide compound having a sulfur atom of a sulfoxide group as an asymmetric center, and the method comprising: a ...  
WO/2021/036851A1
The present disclosure relates to the technical field of electronic components, and provided therein are a nitrogen-containing compound represented by formula (I), an organic electroluminescent device and a photoelectric conversion devic...  
WO/2021/028810A1
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...  
WO/2021/012014A1
The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase e...  
WO/2020/106642A8
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.  
WO/2020/254697A1
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a compo...  
WO/2020/247504A1
Provided herein are compounds of formula (I) which comprise a thiomorpholine 1,1-dioxide or 1-imino-thiomorpholine 1-oxide moiety, or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a c...  
WO/2020/233583A1
The present invention relates to an isoquinolinone compound, which acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1), and the use thereof, and further relates to a pharmaceutical co...  
WO/2020/237063A1
A compound with the following general formula (I) and a general method of making this compound are provided. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are each independently selected from the group that includes H, h...  
WO/2020/227592A1
Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates ar...  
WO/2020/222118A1
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.  
WO/2020/216777A1
The present invention relates to a composition comprising a compound of formula (I) wherein X is selected from the group consisting of S, Se, P, PO, SO, NR1, CR1, CR1R1 or C0-2-alkyl; Z is selected from the group consisting of hydrogen, ...  
WO/2020/211124A1
The present invention relates to a thermally activated delayed fluorescence material, a preparation method therefor, and an organic light-emitting diode device. The structural general formula of the thermally activated delayed fluorescen...  
WO/2020/211121A1
The present invention relates to a thermally activated delayed fluorescence material, a preparation method therefor, and an organic electroluminescent diode device, the structural general formula of the thermally activated delayed fluore...  
WO/2020/163554A1
Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for examp...  
WO/2020/158870A1
The purpose in one embodiment of the present invention is to provide a therapeutic for Parkinson's disease, etc. A compound represented by formulas (1), (2), or (8) or a pharmacologically acceptable salt thereof can be used in the treatm...  
WO/2020/145250A1
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.  
WO/2020/124771A1
The present invention relates to a thermally activated delayed fluorescent compound, a preparation method therefor and an organic electroluminescent diode device thereof. The thermally activated delayed fluorescent compound has a structu...  
WO/2020/117461A1
A composition that includes one or more compounds represented by the formula (A): wherein R1 and R2 are same or different and are the residue of an alkyl group having more than 10 carbon atoms wherein the composition has a viscosity (Kvi...  
WO/2020/106642A1
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.  
WO/2020/094542A1
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...  
WO/2020/082601A1
Disclosed are a dark red photothermally activated delayed fluorescence material, a synthesis method therefor and an electroluminescent device. The dark red photothermally activated delayed fluorescence material is a target compound, whic...  
WO/2020/083327A1
Disclosed in the present invention is an organic compound containing a spirobifluorene structure, having a structure as represented by chemical formula (1), wherein Ar1(Ar2)N-(S1)m- and -(S2)n-NAr3(Ar4) are different, and have symmetrica...  
WO/2020/072377A1
The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin s...  
WO/2020/020178A1
An organic compound as shown in formula (1). Ar 2 has a structural formula as shown in formula (2), and a plurality of Ar 2 may be the same or different. The compound as shown in formula (1) can be used as a luminescent layer material of...  
WO/2020/018929A1
In one aspect, the invention provides compounds and methods that are useful for treating bacterial infections.  
WO/2018/098116A3
A rechargeable electrochemical cell includes a positive electrode having a recharged potential, a negative electrode, and a charge-carrying electrolyte. The rechargeable electrochemical cell further includes an active material having the...  
WO/2019/226490A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2018/226589A9
The disclosure is directed to compounds of the formula (I) and (II) and uses of such compounds to treat, among other conditions, neurodegenerative diseases and cancers.  
WO/2019/185882A1
The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hy...  
WO/2019/183385A1
Provided herein, are compounds, compositions and methods of treatment of cancers using an inhibitor of MAPK/ERK Kinase (MEK), in particular hydrazine derivatives.  
WO/2019/169627A1
Disclosed is a thiazine oligomer as a good grinding stabilizer and anticorrosive coating agent for graphene molecular crystals. Also disclosed is a preparation method for the thiazine oligomer, and a graphene grinding dispersion liquid a...  
WO/2018/152436A8
The present invention provides novel phenazine derivatives, such as compounds of Formula (I) (e.g., Formulae (II) - (XIX)), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be antimicrobial ag...  
WO/2019/152536A1
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.  
WO/2019/129213A1
Disclosed are an amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines. The compound or the ph...  
WO/2019/097503A1
The present invention relates to the treatment of cancer using combination therapy comprising a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), in combination with an ant...  
WO/2019/085684A1
Disclosed in the present invention are a cyanobenzene-containing or thiocyanobenzene-containing compound and applications thereof in organic electroluminescent devices. The compound is formed by cyanobenzene or thiocyanobenzene groups, h...  
WO/2019/063069A1
The invention relates to the use of a compound of formula (I) as described herein as an aromatic substance. The invention also relates to novel compounds of formula (I) as described herein or mixtures comprising at least one different co...  
WO/2019/024339A1
A photosensitizer and derivatives and an application thereof. The photosensitizer has the structure of general formula I, X is S or Se, Y is an organic or inorganic ion, R1 and R2 are respectively independently selected from H, alkyl, al...  
WO/2019/008141A1
The present invention provides a phenothiazine derivative of formula (I) for use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as N.meningitidis,and more specifically for use in preventing and/or ...  
WO/2018/234805A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2018/232675A1
Methylene blue (MB) derivatives selectively detect F-by desilylation reaction to act as a fluorescent probe.  
WO/2018/226589A1
The disclosure is directed to compounds of the formula (I) and (II) and uses of such compounds to treat, among other conditions, neurodegenerative diseases and cancers.  
WO/2018/167185A1
The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5- ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(dimethylamino)-phenothiazin-...  
WO/2018/159459A1
Provided is a diarylamine-based compound represented by a general formula (1) (in general formula (1), A1 and A2 each independently represent an arylene group which has 6-18 carbon atoms and may have a substituent, and A3 and A4 each ind...  
WO/2018/158520A1
Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide, the method resulting in a high purity while being very simple to implement and producing high yields. The method uses phenothiazine as a starting material and compri...  
WO/2017/116903A8
Disclosed herein are methods for preparing ultrapure diaminophenothiasinium compounds with high solubility in solutions, e.g., water, and the compositions provided therefrom.  
WO/2018/156429A1
Lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P), other lanthionine ketimine, lanthionine ketimine phosphonate, and lanthionine ketimine ester derivatives, and methods of making and using the same, ...  
WO/2018/152436A1
The present invention provides novel phenazine derivatives, such as compounds of Formula (I) (e.g., Formulae (II) - (XIX)), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be antimicrobial ag...  
WO/2018/051278A4
The present invention relates to a compound of formula (I) based on enamine derivatives and used as organic hole conductors or hole transporting material in an optoelectronic or photoelectrochemical device. The present invention relates ...  

Matches 1 - 50 out of 3,239